XOMA (XOMA) Falls Modestly Following After-Hours Downgrade
More News related to XOMA
- XOMA Receives NASDAQ Determination Letter
- Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded
- Canaccord Adams Initiates Coverage on XOMA (XOMA) with a Buy; XOMA-052 Promising New Type 2 Diabetes Drug
- XOMA Appoints Jim Neal Vice President of Business Development
- XOMA 052 Selected as a Top Ten Project to Watch
More News related to Downgrades
- Moody's Downgrades Sprint Nextel's (S) Corporate Family Rating; Outlook Negative
- Comverge (COMV) Continuing Lower as Ardour Analyst Cuts to Hold
- Scotia Capital Downgrades New Gold Inc. (NGD) to Sector Underperform
- Craig-Hallum Downgrades ADC Telecom (ADCT) to Accumulate
- Wedbush Downgrades VeriSign (VRSN) to Neutral; Growth Catalysts Not Expected Until 2011
Shares of XOMA Limited (Nasdaq: XOMA) have slid nearly 2% in this evening's extra-market trading session following a downgrade from an analyst at RBC Capital. The firm lowered its investment rating on the stock from Outperform to Sector Perform, but maintained a price target of $1.50.
After closing at $0.712, the stock most recently traded at $0.699.
XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies and other agents to treat inflammatory, autoimmune, infectious, and oncological diseases.
Related Categories
DowngradesStocks Mentioned
-0.05Related Entities
Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Monoclonal Antibodies for Type 2 Diabetes
Michael on Nov 12, 2009 07:54 PMI will be retiring early, thanks to XOMA. What's even better, if I contract Diabetes Type II when I reach 60, being a little overweight, I will live a long life without the need for daily insulin injections. XOMA 052 will change the treatment of all forms of diabetes, as we know it.